Eiko Lifesciences Acquires Majority Stake In SSM Formulations

Eiko Lifesciences Ltd, a specialty chemicals and API manufacturer, has taken a strategic step into the pharmaceutical formulations segment by acquiring a majority stake in SSM Formulations. The board approved the purchase of 51% equity shares for Rs 180 million, marking a significant diversification move. Alongside the acquisition, Eiko also announced plans to raise Rs 218.6 million through issuance of warrants and equity shares at Rs 55 each, reinforcing its capital structure for future growth.  

Key highlights from the announcement include 

• Acquisition of 51% stake in SSM Formulations for Rs 180 million.  
• SSM Formulations will become a subsidiary of Eiko Lifesciences post-acquisition.  
• Board also approved fundraising of Rs 218.6 million via warrants and equity shares at Rs 55 each.  
• The acquisition diversifies Eiko’s portfolio into pharmaceutical formulations, complementing its API and specialty chemicals business.  
• Shares of Eiko Lifesciences surged over 11% on BSE following the announcement, reflecting strong investor confidence.  
• Industry experts note that the move positions Eiko to capture growth opportunities in India’s expanding pharmaceutical sector.  

This acquisition underscores Eiko Lifesciences’ ambition to broaden its footprint in healthcare and pharmaceuticals, aligning with its long-term growth and diversification strategy.  

Sources: ScanX News, Trade Brains, Moneyworks4me